Want to see BEAT full AI Analyst Report?
BEAT Stock Chart & Stats
$0.51
$0.01(2.07%)
At close: 4:00 PM EDT
$0.51
$0.01(2.07%)
Day’s Range― - ―
52-Week Range$0.49 - $4.00
Previous CloseN/A
Volume40.38K
Average Volume (3M)936.14K
Market Cap
$27.79M
Enterprise Value$47.48
Total Cash (Recent Filing)$2.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 13, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding55,506,836
10 Day Avg. Volume1,789,720
30 Day Avg. Volume936,141
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)31.08
Price to Sales (P/S)0.00
P/FCF Ratio-5.55
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.17Price Target Upside520.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.36
Revenue Forecast (FY)$836.20K
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageNo reported debt materially lowers solvency and interest-cost risk, preserving flexibility to pursue licensing, partnerships or clinical programs without immediate debt servicing. Over a 2–6 month horizon this improves optionality for financing choices and reduces forced asset sales under stress.
Extended Runway Via FinancingThe $11.5M financing meaningfully extends liquidity into 2027, reducing near-term financing pressure and enabling continued clinical enrollment, prototype development and selective commercial pilots. This tangible runway extension supports execution on regulatory and commercialization milestones.
Strategic AI & Clinical PartnershipsA deep partnership with Mount Sinai strengthens the firm's AI and clinical credibility, accelerating algorithm development and external validation. Over months this aids regulatory dossiers, differentiation versus competitors, and enhances licensing appeal to OEMs and health systems.
Bears Say
No Reported Revenue; Persistent LossesZero reported revenue and sustained multi-year net losses indicate the company has not yet proven commercial product-market fit. Over 2–6 months this limits internal cash generation, increases reliance on external funding, and heightens execution risk for scaling recurring subscription revenues.
Consistent Negative Cash FlowPersistent negative operating and free cash flow show losses are largely cash-based, not just accounting. This structural cash burn necessitates ongoing financing and constrains reinvestment in sales or R&D, increasing dilution risk and potentially slowing commercialization progress over the next several quarters.
Listing Risk & Weak Equity CushionA Nasdaq minimum-bid deficiency is a structural governance and capital-raising overhang that can limit financing options and strategic counterpart comfort. Coupled with sharply reduced shareholder equity, this elevates delisting and dilution risk, complicating multi-quarter plans for partnerships or commercial scaling.
HeartBeam News
BEAT FAQ
What was Heartbeam, Inc.’s price range in the past 12 months?
Heartbeam, Inc. lowest stock price was $0.49 and its highest was $4.00 in the past 12 months.
What is Heartbeam, Inc.’s market cap?
Heartbeam, Inc.’s market cap is $27.79M.
When is Heartbeam, Inc.’s upcoming earnings report date?
Heartbeam, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 10 days.
How were Heartbeam, Inc.’s earnings last quarter?
Heartbeam, Inc. released its earnings results on May 13, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.135 by $0.015.
Is Heartbeam, Inc. overvalued?
According to Wall Street analysts Heartbeam, Inc.’s price is currently Undervalued.
Does Heartbeam, Inc. pay dividends?
Heartbeam, Inc. does not currently pay dividends.
What is Heartbeam, Inc.’s EPS estimate?
Heartbeam, Inc.’s EPS estimate is -0.09.
How many shares outstanding does Heartbeam, Inc. have?
Heartbeam, Inc. has 55,506,836 shares outstanding.
What happened to Heartbeam, Inc.’s price movement after its last earnings report?
Heartbeam, Inc. reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.135. Following the earnings report the stock price went up 2.97%.
Which hedge fund is a major shareholder of Heartbeam, Inc.?
Currently, no hedge funds are holding shares in BEAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Heartbeam, Inc.
HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.
BEAT Company Deck
BEAT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful operational progress across multiple fronts — financing closed to extend runway, prototype completion and pilot initiations for the 12‑lead patch, enrollment momentum in ALIGN‑ACS, strategic Mount Sinai AI collaboration, and initial commercial anchor partnerships in four target geographies. At the same time, the company remains an early‑stage commercial operation with a Q1 net loss of $4.7M, limited near‑term revenue, reliance on future studies and regulatory approvals for MI indication, and continued cash consumption (though operating cash burn improved 19% YoY and full‑year outflow guidance was reduced to under $16M). On balance, the highlights (funding, clinical progress, partnerships, prototype, AI collaboration, reduced burn) outweigh the lowlights (losses, limited revenue, regulatory and adoption risk), yielding a cautiously positive outlook as the company advances toward de‑risking key milestones.View all BEAT earnings summariesBEAT Stock 12 Month Forecast
Average Price Target
$3.17
▲(520.92% Upside)
Technical Analysis
Ownership Overview
17.10% Insiders
2.61% Mutual Funds
0.75% Other Institutional Investors
75.47% Public Companies and
Individual Investors